logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Maoyan Entertainment (01896.HK) repurchased 740,000 shares at a cost of approximately HK$2.5882 million on October 23.

date
23/10/2026
Zhitong Finance APP News: Maoyan Entertainment (01896.HK) announced that on October 23, 2026, it spent approximately HK$2.5882 million to repurchase 740,000 shares.
Latest
2 m ago
Tuhu-W (09690.HK) repurchased 196,600 shares on October 23 for approximately HK$2.2289 million.
2 m ago
Soloctek Technology (09911.HK) repurchased 228,000 shares for HK$1.974 million on October 23.
4 m ago
American Express third-quarter revenue was $20.06 billion, versus expectations of $20.12 billion. Third-quarter earnings per share were $5.42; third-quarter adjusted earnings per share were $4.68. American Express expects full-year earnings per share of $18.30-$18.60, compared with its previous forecast of $17.30-$17.90. American Express shares rose 0.6% in premarket trading.
4 m ago
Fuan Na (002327.SZ) released its first three quarters results, with net profit attributable to shareholders of RMB 135 million, down 15.39% year on year.
4 m ago
Zai Lab (09688): zocilurtatug pelitecan demonstrates high response rates, encouraging durability, and a well-tolerated safety profile in first-line extensive-stage small cell lung cancer
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.